Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22820Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Karagiannis, A. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Athyros, V. G. | en |
| dc.contributor.author | Kakafika, A. I. | en |
| dc.contributor.author | Tziomalos, K. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:27:31Z | - |
| dc.date.available | 2015-11-24T19:27:31Z | - |
| dc.identifier.issn | 1744-7631 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22820 | - |
| dc.rights | Default Licence | - |
| dc.subject | *Angiotensin Receptor Antagonists | en |
| dc.subject | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | en |
| dc.subject | Animals | en |
| dc.subject | Antihypertensive Agents/pharmacology/*therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hypertension/*drug therapy/*physiopathology | en |
| dc.subject | Metabolic Syndrome X/*drug therapy/physiopathology | en |
| dc.subject | Receptors, Angiotensin/physiology | en |
| dc.subject | Renin-Angiotensin System/drug effects/*physiology | en |
| dc.title | The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1517/14728222.11.2.191 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17227234 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14728222.11.2.191 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | The metabolic syndrome (MetS) is a strong predictor of cardiovascular morbidity and mortality, as well as new Type 2 diabetes. MetS consists of visceral obesity, elevated blood pressure, impaired glucose metabolism, atherogenic dyslipidaemia (elevated triglycerides and low levels of high-density lipoprotein cholesterol), as well as other metabolic abnormalities. The underlying pathophysiology seems to be largely, but not uniquely, attributable to insulin resistance. Existing antihypertensive drugs were designed to lower blood pressure rather than to modify the metabolic abnormalities associated with hypertension. This review considers the role of renin-angiotensin system inhibition and especially the use of angiotensin receptor blockers (ARBs) in the treatment of hypertension in MetS. There are differences among ARBs. Among them is the uricosuric effect of losartan. Furthermore, telmisartan may function as a partial agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). | en |
| heal.journalName | Expert Opin Ther Targets | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
